Etilevodopa hydrochloride
Based on 1 Customer Validation
Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine.
For research use only. We do not sell to patients.
- Purity: 99.40%
- CAS No.: 39740-30-2
- Formula: C11H16ClNO4
- Molecular Weight:261.70
-
Storage:
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
All Dopamine Receptor Isoforms
More
Biological Activity
Etilevodopa (L-Dopa ethyl ester) hydrochloride passes unchanged through the stomach to the duodenum, where it is rapidly hydrolyzed by local esterases to Levodopa and ethanol, and is subsequently absorbed into the blood stream as Levodopa[1].
Compared with standard Levodopa, Etilevodopa hydrochloride has greater solubility in the stomach, faster passage to the small intestine, and a shortened time to maximum Levodopa concentration[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 39740-30-2
-
Appearance Solid
-
Molecular Weight 261.70
-
Formula C11H16ClNO4
-
Color Light yellow to yellow
-
SMILES
N[C@@H](CC1=CC=C(O)C(O)=C1)C(OCC)=O.[H]Cl
-
Synonyms
L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, protect from light, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)
Solvent & Solubility
H2O : 125 mg/mL (477.65 mM; Need ultrasonic)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 25 mg/mL (95.53 mM); Clear solution; Need ultrasonic
Purity & Documentation
-
Data Sheet (270 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Djaldetti R, et al. Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. Clin Neuropharmacol. 2003 Nov-Dec;26(6):322-6. [Content Brief]
[2]. Blindauer K, et al. A randomized controlled trial of etilevodopa in patients with Parkinson disease who have motor fluctuations. Arch Neurol. 2006 Feb;63(2):210-6. [Content Brief]
[3]. Haddad F, et al. Dopamine and Levodopa Prodrugs for the Treatment of Parkinson's Disease. Molecules. 2017 Dec 25;23(1). pii: E40. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 3.8212 mL | 19.1058 mL | 38.2117 mL | 95.5292 mL |
| 5 mM | 0.7642 mL | 3.8212 mL | 7.6423 mL | 19.1058 mL | |
| 10 mM | 0.3821 mL | 1.9106 mL | 3.8212 mL | 9.5529 mL | |
| 15 mM | 0.2547 mL | 1.2737 mL | 2.5474 mL | 6.3686 mL | |
| 20 mM | 0.1911 mL | 0.9553 mL | 1.9106 mL | 4.7765 mL | |
| 25 mM | 0.1528 mL | 0.7642 mL | 1.5285 mL | 3.8212 mL | |
| 30 mM | 0.1274 mL | 0.6369 mL | 1.2737 mL | 3.1843 mL | |
| 40 mM | 0.0955 mL | 0.4776 mL | 0.9553 mL | 2.3882 mL | |
| 50 mM | 0.0764 mL | 0.3821 mL | 0.7642 mL | 1.9106 mL | |
| 60 mM | 0.0637 mL | 0.3184 mL | 0.6369 mL | 1.5922 mL | |
| 80 mM | 0.0478 mL | 0.2388 mL | 0.4776 mL | 1.1941 mL | |
| 100 mM | 0.0382 mL | 0.1911 mL | 0.3821 mL | 0.9553 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.